Curis, Inc. (NASDAQ: CRIS), a biotechnology company specializing in the development of innovative cancer therapies, announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, before the market opens. Following the announcement, management will host a conference call and simultaneous webcast at 8:30 a.m. ET to discuss the results and provide a corporate update on its clinical programs.
Focus on Emavusertib Development
The company's primary focus is on emavusertib (CA-4948), an orally available, small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 is a key signaling protein involved in inflammation and cancer, making it a promising therapeutic target.
Ongoing Clinical Trials
Curis is currently evaluating emavusertib in several clinical trials:
- TakeAim Lymphoma Study (Phase 1/2): This study is investigating emavusertib in combination with the BTK inhibitor ibrutinib for patients with relapsed or refractory primary central nervous system lymphoma (PCNSL).
- TakeAim Leukemia Study (Phase 1/2): This trial is assessing emavusertib as a monotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) and relapsed or refractory high-risk myelodysplastic syndrome (hrMDS) with specific mutations (FLT3, U2AF1, or SF3B1).
- Frontline AML Combination Therapy: Emavusertib is also being evaluated in combination with azacitidine and venetoclax as a frontline therapy for patients with AML.
Orphan Drug Designation
Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of AML and MDS, highlighting the unmet need for effective therapies in these diseases.
Collaboration and Licensing
Curis has an exclusive license to emavusertib through its collaboration with Aurigene, established in 2015. Additionally, Curis licensed its rights to Erivedge to Genentech (a member of the Roche Group), which is commercializing the drug for advanced basal cell carcinoma.
